The L’Oréal-UNESCO For Women in Science programme has announced its 2026 Singapore grantees, recognising th...
Abbott, the global healthcare leader, and Novo, a global leader in treatments for serious chronic diseases, have announc...
Boehringer Ingelheim, headquartered in Germany, and China-based Sino Biopharmaceutical (together with its subsidiaries, ...
Japan-based Nxera Pharma has announced that its subsidiary, Nxera Pharma UK, has entered into an exclusive global licens...
Minghui Pharmaceutical and ASKA Pharmaceutical have entered into an exclusive license agreement for the development and ...
Illumina has announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a coho...
QIAGEN has announced that its QIAsprint Connect and QIAseq FX DNA Library Kit will support automated DNA extraction and ...
CellProthera, a clinical-stage company developing regenerative cell therapies for ischemic diseases, has announced its s...
Japan-based pharma firm Shionogi has announced that Shionogi China, a Shionogi group company in China, has entered into ...
DKSH has signed an agreement to acquire 100% of NewBridge Pharmaceuticals, a Dubai-headquartered healthcare commercialis...
US-based BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with South Korea-based G...
Australia-based Firebrick Pharma has announced the launch of its third product in the Nasodine range: Nas...
Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 1.06 b...
SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...
SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...
In 2026, Novo Nordisk’s Awiqli became the first once-weekly basal insulin to receive approval from the US Food and...
American multinational pharmaceutical company Merck (Known as Merck Sharp & Dohme or MSD outside the United States a...
If Day 1 of BIX 2026 asked what makes a Korean asset partnerable, Day 2 asked what happens once someone wants it. Thursd...
Japan-based Astellas Pharma Inc. has entered into an exclusive option and license agreement for DAX-044, Audax’s l...
PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development o...
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Novartis ha...
BIOPLUS-INTERPHEX KOREA 2026 opened at COEX in Seoul on Wednesday with a first day that made its priorities plain. Hoste...
US-based Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral IL-23R inhibitor programme, in...
HighTide Therapeutics, Inc., an innovative biopharmaceutical company specializing in the development of multifunctional,...
Singapore’s biopharmaceutical industry has launched a S$4.8 million study award to strengthen its manufacturing ta...
